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Objectives: To explore the impact of market competition on pharmaceutical pric-
ing, and to further investigate the determinants of pharmaceutical price in Chinese 
pharmaceutical market. MethOds: Anti-infective pharmaceutical data were 
extracted from inpatient claims in Tianjin Urban Employee Basic Medical Insurance 
(UEBMI) database from 2006 to 2010. Based on product-quarter data, a quasi-hedonic 
regression model was used to estimate the impact of market competition, which 
is defined by generic competition (the number of manufacturers within the same 
generic market) and therapeutic competition (the number of molecules in the ATC3 
therapeutic category). The inputs to our model were specific attributes of the products 
and manufacturers, with the exception of competition variables. Defined daily dose 
(DDD) was used as the standard quantity unit and the price per DDD was used as the 
price unit. Results: Our results indicated that pharmaceutical prices were inversely 
related to the number of generic competitors, but positively related to the number 
of therapeutic competitors. The prices of patent drugs and the off-patent drugs from 
original manufacturer were significantly higher than the prices of generic drugs. 
We also found the positive relationship between DDD and price, and the negative 
relationship between pack size and price which implied that manufacturers com-
pete on volume discounts on large pack size. In addition, product age was inversely 
related to product price. In terms of manufacturers’ attributes, the results suggested 
that the prices of products imported by the foreign manufacturers and produced by 
joint-venture firms were higher than those of products from local manufacturers, and 
the prices of products from domestic 100 top-selling manufacturers were lower than 
those of products from non-top 100 local manufacturers. cOnclusiOns: Generic 
market competition still plays an important role in determination of regulated phar-
maceutical prices in China. The drug attributes, manufacturers’ attributes and market 
competition are jointly determined pharmaceutical price.
PHP7
Price comParison Between tHe essential and non-essential  
anti-infective medicines among national reimBursement  
drug list in cHina
Ma F.F., Wu J., Zhao M.Y.
Tianjin University, Tianjin, China
Objectives: To compare the price changes of the essential and the non-essential 
anti-infective medicines in Tianjin, China using index method. MethOds: Data were 
extracted from inpatient claims in Urban Employee Basic Medical Insurance data-
base of Tianjin, China, from 2006 to 2010. Price indices were measured by Fisher and 
chained Fisher index formulas by quarter. The quantity weight unit was defined daily 
dose (DDD) and the price unit was the price per DDD. Price indices were calculated 
both at molecule level (defined by active ingredient) and product level (defined by 
molecule, strength, preparation, and manufacturer). Results: The data contained 
41 molecules and 786 products among the essential anti-infective medicines, and 81 
molecules and 636 products among the non-essential anti-infective medicines. For 
the essential anti-infective medicines, the price index decreased to 0.90 (in chained 
Fisher index at molecule level) from 2006 Q1 to 2010 Q4, and the price index for the 
non-essential anti-infective medicines decreased to 0.73 (in chained Fisher index 
at molecule level) during the same period. For the essential and non-essential anti-
infective, the results of chained Fisher and unchained counterparts were similar 
(10% vs. 10% for the essential and 28% vs. 27% for the non-essential at molecule 
level). The price indices at molecule level decreased slower than the counterparts at 
product level (10% vs. 24% for the essential and 27% vs. 30% for the non-essential in 
chained Fisher index). cOnclusiOns: The price of the essential and non-essential 
anti-infective medicines among national reimbursement drug list had decreased in 
Tianjin, China, but the price of the essential anti-infective medicines decreased slower 
than the non-essential anti-infective medicines.
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imPact of drug Policy on imProving access to medicines in delHi
Bhoi N.
IPE Global, DFID supported Health Sector Reforms Programme, Bhubaneshwar, India
Objectives: To assess the impact of drug policy on improving access to essential 
medicines in Delhi MethOds: The quantity of drugs procured from the Essential 
Drugs List (EDL) and outside the EDL; money spent on these; changes in stock out 
days for the key drugs. The implementation strategy includes elements of drug 
policy like use of EDL & STG, improved procurement system, training on drugs 
management & rational use of drugs. Retrospective data collected from stock reg-
isters. The data for two years before (1993-1994, 1994-1995) and two years after 
(2000-2001, 2001-2002) the drug policy was assessed. Data collected from two large 
public sector hospitals in Delhi that serve a large section of the population through 
convenient purposive sampling method. Results: After the implementation of 
the drug policy, the availability of drugs increased by 25% in the large and 98% in 
the medium hospital. The drugs procured from the EDL increased from 62% to 78% 
in the large and 74% to 87% in the medium hospital. Of the total expenditure, the 
money spent on essential drugs increased from 73% to 85% in the large and 87% to 
93% in the medium hospital, whereas money spent on nonessential drugs decreased 
from 27% to 15% in the large and 13% to 7% in the medium hospital. The average 
number of stock out days for key dugs decreased from 33 to 16 days in the large 
and from 143 days to 33 days in the medium hospital. The utilization pattern of 
health services by patients increased by 8% in the large and by 35% in the medium 
hospital. cOnclusiOns: The implementation of the drug policy in the state of 
Delhi increased availability of essential drugs. This kind of intervention can serve 
as a model for improving access to medicines by implementing an effective drug.
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tHe imPact on drug Price and Patient selection of national 
essential drug system: evidence from inPatient records from 
insurance reimBursement data
Du N., Xu J.
Southwest University of Finance and Economics, chengdu, China
Objectives: Diagnosis related groups (DRG) like financing method was introduced in 
Hungary in 1993 for acute care hospital reimbursement. Due to the increased activity 
of the hospitals, an upper ceiling, the so called performance volume limit (PVL) was 
introduced in acute care hospital financing in 2004. The aim of our study was to ana-
lyze the effect of performance volume limit on DRG based hospital financing on the 
example of a Hungarian tertiary teaching hospital, the Clinical Centre of the University 
of Pécs. MethOds: Data derived from the financial database of the National Health 
Insurance Fund Administration, the only health care financing agency in Hungary. 
We analyzed the proportion of hospital activity over the performance volume limit 
ceiling. We calculated the proportion of hospital activity over that ceiling measured by 
DRG cost-weights. The period 2004-2013 was involved into the study. Results: The 
annual number of patients varied between 72671 (2007) and 82509 (2009) at the Clinical 
Centre of the University of Pécs. During the same period the annual performance 
volume limit for DRG costweigths varied between 97784 and 116970. However due to 
the regulation of the upper ceiling of hospitals’ activity, 3.0 % (2007) to 14.9 % (2009) of 
that activity has not been reimbursed to the Clinical Centre. The average loss of reim-
bursement due to performance volume limit was 7.2 % of annual revenues between 
2004-2013. cOnclusiOns: The introduction of performance volume limit into the 
DRG based hospital financing resulted in a partial loss of hospitals’ revenues. Despite 
of in PVL regulation, the Clinical Centre of the University of Pécs did not reduced its 
output, thus the annual number of patients did not declined in this hospital.
HealtH care use & Policy studies – disease management
PHP4
co-administration of turmeric Potentiates Preventive effect of 
Black seeds in metaBolic syndrome
Gilani A.H., Amin F., Mehmood M.H.
The Aga Khan University, Karachi, Pakistan
Objectives: The metabolic syndrome (MS), a combination of metabolic abnormali-
ties including obesity, diabetes, dyslipidemia and hypertension is associated with 
an increased risk of coronary heart disease and stroke. Complementary medicines 
including herbs like Turmeric and Black seeds (Nigella sativa) can be used to pre-
vent or as an adjuvant to control MS with fewer side-effects, better acceptability 
and cost effectiveness. This study determines if the co-administration of Turmeric 
potentiates the beneficial effects of black seeds on MS in rats. MethOds: Black seeds 
and Turmeric alone and in combination at different dosages were administered to 
fructose-fed rats. Blood pressure, fasting sugar and lipid profile were measured 
before and after 3 and 6 weeks of treatment. Serum insulin and endothelial func-
tion were determined at 6 weeks of intervention Results: Black seeds at the dose 
of 0.6 g/kg prevented hypertension at week 3 of intervention, while at 6 weeks it 
prevented hypertension, hyperglycemia, dyslipidemia and endothelial dysfunction. 
Turmeric at 3 g/kg dose prevented dyslipidemia but not hypertension. The combi-
nation of 0.3 g/kg Black seeds and 1.5 g/kg Turmeric prevented hypertension and 
hypertriglyceridemia at week 3 but provided a wide coverage at 6 weeks including in 
hypertension, hyperglycemia, dyslipidemia, hyperinsulinemia and endothelial dys-
function. cOnclusiOns: This study showed that co-administration of Turmeric and 
Black seeds resulted in enhanced efficacy in correcting metabolic syndrome when 
compared with each component used alone, while the reduced dose of individual 
component when used in combination is likely to reduce the side-effects.
PHP5
PHarmacological Basis for tHe medicinal use of almonds in 
cardiovascular disorders
Gilani A.H.1, Jamshed H.2
1The Aga Khan University, Karachi, Pakistan, 2Department of Biological and Biomedical Sciences, 
The Aga Khan University, Karachi, Pakistan
Objectives: Though almonds are shown to be effective in cardiovascular disorders 
(CVDs), but there is limited information on the possible mode of action. This study 
aimed at exploring, in multiple rat models, the pharmacological basis for the medici-
nal use of almonds in CVDs. MethOds: Tyloxapol, high-fat diet (HFD) and fructose 
models were used. Group 1 in each study was normal control and group 2 and 3 were 
diseased groups. Almonds were given for four weeks to group 3 of each study, after 
which blood was collected for biochemical estimations. Liver from rats of tyloxapol 
study and thoracic aorta from rats of HFD study were isolated for enzyme assays and 
vascular reactivity. Results: Almonds supplementation significantly (p < 0.05) pre-
vented hyperlipidemia in all the three rat models. In tyloxapol-induced hyperlipidemia 
model, almond supplementation inhibited HMG-CoA activity. It also improved lipid 
profile and prevented HFD-induced increase in serum biomarkers of liver dysfunc-
tion (amino-transferases) and endothelial dysfunction (uric acid, phosphorus, alkaline 
phosphatase and gamma glutamyl transferase) as well as restored endothelial reac-
tivity. Almonds also demoted the HFD-induced inhibition of endothelial nitric oxide 
synthase enzyme, thereby, promoting serum nitric oxide release. In the fiber-free while 
flour with fructose model, improvement in serum HDL was observed, in addition to 
improvement in other markers of lipid abnormality. cOnclusiOns: Almond sup-
plementation demonstrated cardio-protection and antidyslipidemic effect mediated 
through multiple pathways including inhibition of cholesterol synthesis and restora-
tion of hepatic and endothelial function, while the use of multiple animal models aided 
in gaining insights on some of the possible mechanism of actions.
HealtH care use & Policy studies – drug/device/diagnostic use & Policy
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PHarmaceutical Pricing and market comPetition: an emPirical 
study Based on anti-infective drugs in tianjin, cHina
Zhao M.Y., Wu J., Ma F.F.
Tianjin University, Tianjin, China
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  A787
PHP12
review of reference Pricing effects on PHarmaceuticals
Zhou W., Cui X., Qian Y.
Sanofi China, Beijing, China
Objectives: Reference pricing has been popular used in many countries as a reim-
bursement policy to contain raising pharmaceutical expenditures since Germany 
first introduced in1989. China is under discussion concerning implementation of 
reference pricing for innovative drug pricing. This study is designed to overview 
the effects of reference pricing on health care helps to provide reference evidence 
to estimate the potential role of reference pricing for policy strategy making, and 
deliver the suggestion on benefit/risk analysis when adopting reference pricing in 
China. MethOds: We systematic reviewed published review studies or literatures 
based on empirical outcome effects analysis of reference pricing and present the 
common assess conclusion or views on the effect of reference pricing across all 
experiences, selected research covered different countries and backgrounds have lit-
tle coverage to keep the references outcomes diversity and little overlap. Results: 
Results shows that reference pricing could decreases drug prices include in system 
and original and generic drug price reductions are different according to pharma-
ceutical markets power. Reference pricing increases drug use of priced below or at 
the reference price. Reference pricing could save drug expenditures limited in the 
short-run but no sufficient evidence showed on the long-term expenditures reduc-
tion. Besides, no adverse effect was clearly found on patient access pharmaceutical 
services by reference pricing. cOnclusiOns: Evidences indicates that reference 
pricing seems to be effective for governments to contain pharmaceutical expendi-
tures and more research is need on the long-term effects and impact on different 
health care systems of reference pricing.
PHP14
Questionnaire analysis on PHarmacists role and drug 
reimBursement list adjustment mecHanism under tHe current 
cHina HealtH insurance system
Song R.1, Xuan J.2, Chen C.1, Wang M.1, Xie X.3
1China Pharmaceutical Research and Development Association, Beijing, China, 2Fudan University, 
School of Public Health, Warren, NJ, USA, 3Pfizer China, Beijing, China
Objectives: To study how to adjust the roles of pharmacists under the currently 
health insurance system; and how to perfect the mechanism for drug reimbursement 
list adjustment under China. current social health insurance system MethOds: 
China Pharmaceutical Industry Research and Development Association formulated 
the Questionnaire on the Roles of Pharmacists and the Health Insurance System. Survey 
was conducted to pharmacists and experts in relevant fields from early April 2013. 
By the middle of May, 152 questionnaires were returned, in which 141 ones were 
considered effective for the statistics. Results: As to the pharmacist system, 95% 
respondents agree to popularize the pharmacist system comprehensively in the 
hospitals. Respondents believe that pharmacists shall be entitled to the rights of 
verifying prescriptions, examining medication cost information, dispensing high 
quality drugs with preference, and participating in RDL adjustment. The majority 
of respondents (81.6%) agree to link the medical institutions and medical insurance 
agencies on line, which can better take advantage of pharmacistsrole. As to the RDL 
adjustment cycle, most respondents (78.7%) believe that current 4-year cycle is not 
reasonable, and more people (46.8%) think 2 years may be better. The respondents 
think that major problems in current RDL adjustment mechanism lie in the lack of 
evaluationstandards and procedures transparency. More people (61.0%) agree that 
the pharmacoeconomics evaluation shall be an essential basis for RDL adjustment 
decisions process. The survey results also show that at present, the system design 
for pharmacoeconomics application is not mature, and relevant capacity building 
and legislative guarantee are urgently required. cOnclusiOns: It has been a com-
monly recognization to improve the pharmacist system and strengthen the rights 
of pharmacist in prescription examination and drug dispensing. Evidence-based 
researches on how to shorten adjustment cycle, establish a transparent and open 
decision-making process, and attach importance to the pharmacoeconomics are 
major issues needing improvements in the present RDL adjustment mechanism.
PHP15
How do organizational arrangements of tHe PHarmaceutical 
suPPly system affect availaBility to essential medicines  
in rural cHina?
Zuo G.
Shandong University, Jinan, China
Objectives: The manifold reasons lead to lack of availability to essential medicines, 
but higher price induced by pharmaceutical patent and organizational arrange-
ments of pharmaceutical supply system is main barrier. Since 2009, Chinese govern-
ment has constructed essential medicines policy of centralized purchasing, uniform 
distribution and “zero-mark-up” (i. e. no-profit) sale to supply essential medicines, 
all but generic drugs. This study aims to develop a theoretical methodology to 
examine the impact of organizational arrangements on availability to essential 
medicines. MethOds: We present a theoretical framework based on organizational 
economics to identify organizational boundary and inter-organization relationship 
of pharmaceutical supply system in order to define the stakeholders’ function and 
to find competition and cooperation relationship between them. We collect evidence 
from nine township hospitals at three counties of Shandong Province with different 
economic and geographical environment from July to August 2011. Organizational 
arrangements are identified by document review, interviews and focus group discus-
sions with stakeholders. Availability to essential medicines is measured as allocated 
rate and timeliness arrival rate of national essential medicines by questionnaire and 
online transaction records. Results: The mean allocated rate of national essential 
medicines was 51.47% because organizational boundary between stakeholders was 
so vague that the stakeholders’ function was not clear and pharmaceutical manu-
facturers didn’t receive the demand information of township hospitals. Timeliness 
arrival rate of national essential medicines within three days was from 33.77% 
Objectives: This study estimates the effect of national essential drug system on 
drug price and patient selection of pilot grass-root medical institution. MethOds: 
This study employs DID (difference-in-difference) method to investigate the effect 
of Essential Drug Regime Reform (EDRR) on drug price and patient selection of 
public grass-root medical institutions. Our sample comes from a Chinese city’s 
Urban Employee Basic Medical Insurance Reimbursement Dataset for inpatient 
care from 2009-2010. The full sample has 53416 observations including 2896 unique 
pharmaceutical firm-level products from 210 grass-root medical institutions. The 
dependent variable is the average price of each product in each month from each 
medical institution. The key independent variables are dummy variables indicating 
the pilot institutions (TREAT), the releasing time of Essential Drug Regime (EDR) 
and interaction of them (TREAT*EDR). Results: The results show that after the 
implementation of EDR, drug price on the pilot institutions decreased significantly 
by 37 percent (relative to control institution). Especially, essential drugs fell by 
43.3 percent relative to control institution. This policy has no significant effect on 
non-essential drugs. After the implementation of the national essential drug sys-
tem inpatient expenditures of the pilot medical institutions increased by 20.67%, 
length of stays increased by about three days, relative to the non-pilot medical 
institutions. After all, there is no change in patient co-payment rate. We found that 
patients more severe (diagnosed with more than one diseases) chose to go to the 
pilot medical institution increased by 7%. cOnclusiOns: The national essential 
drug systerm has signifcant effect on durg price, especially the essential drug, 
and the patients more severe prefered to go to the grass-root medical institution 
rather than levle-2 and level-3 hospitals.
PHP10
an analysis of determinants of new and Bland-name drugs 
PrescriPtion BeHavior among jaPanese PHysicians
Ma X., Kakihara H.
Kyoto University, Kyoto, Japan
Objectives: Japanese government has promoted the use of generic drugs as 
means to decrease the burden to patients as well as to improve the situation of 
public finance sustainability. However, the proportion of generic prescriptions out 
of the total prescriptions written is lower compared to other developed countries. 
We thus examine the determinants of prescription of new and brand name drugs 
to understand what discourages Japanese physicians from prescribing generic 
drugs. MethOds: Using data from an original survey of 300 physicians conducted 
in September 2012. These surveys are analyzed with regard to the potential influ-
ence of the following factors: physicians’ information seeking behavior regard-
ing drugs, principal-agent relationship, risk and time preferences and physician 
characteristics. The analysis uses an ordered logistic regression model. Results: 
Our major findings are summarized as follows. First, it can be said that the propor-
tion of new drug prescriptions to all prescriptions rises as physicians’ intensity 
in information seeking behavior increases, but it is not significantly affected by 
principle-agent relationship or risk or time preferences. Second, the proportion of 
brand name drug prescriptions is positively associated with increased consideration 
of drug safety but negatively associated with that of drugs costs, pointing toward 
the hypothesis that the principal-agent relationship is an important factor. Third, 
time preference significantly determines the prescription of brand name drugs 
whereas risk preference does not. In particular, the more preferred is current con-
sumption over future consumption, the greater proportion of brand name drugs is 
prescribed. Neither risk nor time preferences significantly affects the proportion 
of prescription of new drugs. Finally, the impact of each determinant on prescrip-
tion behavior differs between internal medicine physicians and physicians in other 
areas of specialization. cOnclusiOns: Our empirical results suggest a limitation 
of uniform policies across physicians such as provision of financial incentives as 
means to the promotion of generic drug use.
PHP11
review on medicines Prices and availaBility in indonesia: 2004  
to 2012
Siahaan S., Handayani R.S.
National Institute of Health Research and Development (NIHRD), Jakarta Pusat, Indonesia
Objectives: In 2014 Indonesia started National Health Insurance (NHI). This 
study aimed to search the existing evidence base on access to medicine issues to 
recommend policy options and model of medicines prices to be used in the era 
of NHI. MethOds: NIHRD conducted study at 2012 by reviewing several surveys 
results of access to medicines from 2004-2012 and organising several discussion 
forums about access to medicines. The participants were key persons from govern-
ment, private sectors, NGOs and other related stakeholders. Results: Indonesia 
medicines prices surveys using WHO-HAI method in 2004, 2010 and 2012 showed 
access to medicines problems still had similar patterns i. e. several district health 
offices bought medicines with higher prices than national standard prices and sev-
eral public hospitals sold several medicines with higher prices than private sectors. 
Most medicines prices (> 90%) were still higher than international reference price. 
The Median Price Ratios (MPRs) of medicines for public sector in Indonesia were 
1.74 (2004) and 1.52 (2012), while in Malaysia was 1.09 (2004) and in Thailand was 
1.46 (2006), but in Philippine was 2.06 (2009). The availability of medicines in public 
sectors was consistent lower than in private sectors. Study (2007) showed the avail-
ability of several essential and generic medicines in several public health facilities 
were enough for < 3 months. Study (2011) showed availability of FDC medicines for 
tuberculosis and ACT for malaria in endemic areas were inadequate (50%&70%). 
Discussion forums summarized main points: Medicines prices can be controlled 
by full time pharmacist if they serve rational drug use to patients. NHI has ability 
to control medicines prices, etc. cOnclusiOns: Pharmacy should not “mark-up” 
medicines prices, but charge pharmacist services fee to patients. The government 
should set up MPRs of medicines in the list of NHI formulary no more than 1.50 
and assure its availability, and NHI should implement pharmacoeconomics for new 
medicines.
